Evaluation of HALP Score in Distinction Between FGR & SGA

Status Completed

Clinical Trial Summary

Fetal Growth Restriction (FGR) and Small for Gestational Age (SGA) are two conditions that can happen when a baby doesn't grow as much as expected during pregnancy. FGR is caused by things like problems with the mother's nutrition and inflammation, while SGA is usually because of genetic and other factors. It's important to know if a baby has FGR or SGA because FGR babies can have more health problems and are at risk of dying before or shortly after birth. SGA babies are usually healthy, but they might have more health problems later in life. Doctors can use a simple blood test called the HALP score to see if a mother has problems with her nutrition and inflammation. However, it hasn't been studied for FGR and SGA. We want to study if the HALP score can help us tell if a baby has FGR or SGA by looking at the mother's blood test results.

Clinical Trial Description

Fetal Growth Restriction (FGR) and Small for Gestational Age (SGA) are two conditions that are commonly encountered in obstetrics. FGR is defined as a condition in which the fetus is smaller than expected for its gestational age, and its pathophysiology is thought to be influenced by both maternal inflammation and nutritional status. On the other hand, SGA is a condition in which the fetus is smaller than expected, but its pathophysiology is primarily attributed to constitutional and genetic factors. It is important to distinguish between FGR and SGA because FGR is associated with a higher risk of adverse fetal and neonatal outcomes, including morbidity and mortality. In contrast, SGA infants are generally healthy, but may have a higher risk of long-term health problems, such as hypertension and diabetes. The HALP score is a simple and easily calculated index that is based on the levels of hemoglobin, lymphocytes, albumin, and platelets. It has been shown to be informative about the nutritional and inflammatory status in various medical fields. However, its use in obstetrics is limited and its potential to distinguish between FGR and SGA has not been studied. Given that maternal inflammation and nutritional status are also involved in the pathophysiology of FGR, it is possible that the HALP score could be useful in distinguishing between FGR and SGA. Therefore, we plan to investigate the potential of the HALP score in differentiating between these two conditions. ;

Study Design

Related Conditions & MeSH terms

Fetal Growth Restriction
Fetal Growth Retardation
Small for Gestational Age at Delivery

Clinical Trial Details

NCT number	NCT05814198
Study type	Observational
Source	Prof. Dr. Cemil Tascioglu Education and Research Hospital Organization
Contact
Status	Completed
Phase
Start date	February 22, 2023
Completion date	June 15, 2023

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05934318` - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)	N/A
Recruiting	`NCT05601375` - Speckle Tracking Echocardiography in Infants, Prenatally and Postnatally
Recruiting	`NCT03662178` - Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
Completed	`NCT05059093` - Developing and Testing AI Models for Fetal Biometry and Amniotic Volume Assessment in Fetal Ultrasound Scans.
Completed	`NCT03067298` - Prediction of Preeclampsia and Other Pregnancy Complications Following Combined Iterative Screening
Recruiting	`NCT01981824` - Prediction of Growth Restricted Fetuses Using Femur Length to Mid-thigh Circumference Ratio: A Case-control Study	N/A
Recruiting	`NCT04215107` - Fetal Distribution of Feto-placental Blood Flow Related to Placental Nutrient Transport and Maternal Food Intake	N/A
Completed	`NCT02189148` - First-trimester Prediction of Preeclampsia
Terminated	`NCT04084990` - Sleep Apnea and Fetal Growth Restriction	Phase 3
Recruiting	`NCT04051567` - Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies	Phase 4
Recruiting	`NCT04394611` - Metals and in Fetal Growth Restriction
Completed	`NCT01369940` - The NICHD Fetal Growth Study: Twin Gestations	N/A
Not yet recruiting	`NCT03121196` - Social Deprivation and Pregnancy	N/A
Recruiting	`NCT03177824` - Sildenafil Citrate for Treatment of Growth-restricted Fetuses	Phase 3
Completed	`NCT02379832` - Pre-Eclampsia And Growth Restriction: a Longitudinal Study
Completed	`NCT02379494` - First Trimester Prediction of Preeclampsia and Fetal Growth Restriction	N/A
Completed	`NCT03046355` - Timing of Delivery in Fetal Growth Restriction of Uncomplicated Women	N/A
Not yet recruiting	`NCT05848869` - Prostaglandins Versus Trans-cervical Balloon for Induction of Labor in Fetal Growth Restriction	N/A
Not yet recruiting	`NCT05674487` - Prostaglandins Versus Trans-cervical Balloon for Induction of Labor in Fetal Growth Restriction (PROBIN)	N/A
Recruiting	`NCT04438668` - Evaluation of the Safety and Performance of Centaflow	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation of HALP Score in Distinction Between FGR and SGA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms